Posted by Michael Wonder on 26 Apr 2021
FDA to scrutinise unproven cancer drugs after 10 year gap
26 April 2021 - U.S. regulators are convening a meeting to consider clawing back approvals from several cancer drugs that have failed to show they extend or improve life.
Each year the U.S. approves dozens of new uses for cancer drugs based on early signs that they can shrink or slow the spread of tumours.
